Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Relatlimab or Urelumab Alone and in Combination with Nivolumab in Treating Patients with Recurrent Glioblastoma

Trial Status: administratively complete

This phase I trial studies the safety and best dose of relatlimab or urelumab alone and in combination with nivolumab in treating patients with glioblastoma that has returned (recurrent). Monoclonal antibodies, such as relatlimab, urelumab, and nivolumab may interfere with the ability of tumor cells to grow and spread.